Top Markets
#1 Black Phoenix Black Phoenix +167.48%
#2 Islamic Coin Islamic Coin +158.25%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +43.60%
#5 Cryptopia Cryptopia +20.92%
#6 Quantum Resistant Ledger Quantum Resistant Ledger +18.51%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.45%
#8 Test Test +17.66%
#9 Victoria VR Victoria VR +12.65%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +10.37%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Arno Therapeutics, Inc. Arno Therapeutics, Inc.

Arno Therapeutics, Inc.

ARNI
Rang in Aktien #42094
Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a... Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials. This therapeutic is being investigated for its efficacy in treating various solid tumors, such as breast and endometrial cancers in post-menopausal women, and advanced castration-resistant prostate cancer in men. AR-12, an orally administered cancer therapy, has successfully completed Phase I clinical studies for solid tumors and hematological malignancies. Additionally, it is in pre-clinical development for potential applications against a range of microbial targets. AR-42, another innovative oral cancer treatment, is involved in a Phase I investigator-initiated clinical study, targeting both hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established licensing agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. The company also holds a co-development partnership with Leica Biosystems Newcastle Ltd.
Aktienkurs
$0.0001
Zuletzt synchronisiert: 2026-08-11
Marktkapitalisierung
$4.94K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Arno Therapeutics, Inc. (ARNI)

Kategorie

Healthcare
Kursverlauf für Arno Therapeutics, Inc. (ARNI)
Höchster Schlusskurs: $0.00 am 2026-08-01

Niedrigster Schlusskurs: $16.00 am 2008-06-01
Kursverlauf der Aktie von Arno Therapeutics, Inc. von 2008 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 0.00%
2025 63.64%
2024 -94.64%
2023 186,370.59%
2022 -99.95%
2021 -24.95%
2020 30.12%
2019 -10.49%
2018 -92.79%
2017 -84.04%
2016 -38.28%
2015 -47.11%
2014 -77.91%
2013 -27.61%
2012 -66.67%
2011 194.12%
2010 -49.00%
2009 -69.23%
2008 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $527.87 33.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $873.57 35.10%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $736.38 7.69%
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $263.09 18.09%
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.08K -6.98%
KR